# BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

> **NCT06741072** · PHASE1 · SUSPENDED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 55 (estimated)

## Conditions studied

- Chronic Kidney Disease, Stage 4
- Chronic Kidney Disease, Stage 5
- EBV-Related Lymphoproliferative Disorder
- EBV-Related Malignant Neoplasm
- Post-Transplant Lymphoproliferative Disorder

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Dulbecco''s Phosphate-Buffered Saline
- **BIOLOGICAL:** Peptide Vaccine
- **BIOLOGICAL:** QS21

## Key facts

- **NCT ID:** NCT06741072
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-07-15
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Why stopped:** study drug issue
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06741072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06741072, "BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06741072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*